LSD-Assisted Psychotherapy in Patients with Terminal Cancer
The DOI matches its Crossref record.
Abstract
The paper describes the results of a clinical study exploring the potential of a complex psychotherapeutic program utilizing psychedelic compounds to alleviate the emotional and physical suffering of cancer patients. A total of 60 cancer patients participated in this experimental study. In 44 of these patients, LSD (200-500 p%per os) was administered as an adjunct to psychotherapy; in 19 patients, a new psychedelic compound, dipropyltryptamine (DPT) was administered (60-105 mg i.m.). Three of these patients received both LSD and DPT administered on different sessions. The therapeutic results were assessed by means of a rating scale reflecting the degree of the patients’ depression, psychological isolation, anxiety, difficulty in management, fear of death, and pain. The ratings were done by attending physicians, nurses, family members, LSD therapists and cotherapists, and independent raters. In addition, the amount of narcotics required in the management of the patient was measured before and after the psychedelic sessions. Systematic rating was carried out in a group of 31 cancer patients treated by LSD. The comparison of the means of individual ratings from pre- to posttreatment showed significant improvement in all the measured parameters for most of the raters. There was a definite reduction of the narcotic medication; it did not, however, reach the level of statistical significance. The pre- to post-treatment comparison of the global indexes used as gross indicators of the degree of emotional and physical distress, indicated that approximately 29 % of the patients showed dramatic improvement, and another 41.9 % moderate improvement, with 22.6 % essentially unchanged. In 6.4 % of the patients, global indexes showed a decrement in the posttherapy ratings.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Post-treatment, patients showed 'dramatic improvement' (29%) and 'moderate improvement' (42%), or remained 'essentially unchanged' (29%).”
From Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review (2022) · cites this paper as Grof et al., 1973
In the citing paper
“No serious adverse effects were reported.”
From Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review (2022) · cites this paper as Grof et al., 1973
In the citing paper
“Overall, improvements were reported on anxiety, depression, and social isolation.”
From Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review (2022) · cites this paper as Grof et al., 1973
In the citing paper
“Additionally, while we found some qualitative studies detailing patient experiences with classical psychedelics (Grof et al., 1973;Agin-Liebes et al., 2020;Belser et al., 2017), no qualitative studies on ketamine treatment in terminally ill patients were encountered in the literature.”
From Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review (2022) · cites this paper as Grof et al., 1973
Citations
Cites
Still being checked.
Cited by
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201
“Several unblinded studies in the 1960s and 70s suggested that such compounds might be effective in treating psychological distress in cancer patients (Grof et al., 1973; Kast, 1967; Richards et al., 1977); however, these studies did not include the comparison conditions that would be expected of modern psychopharmacol…”
BackgroundSelf-citationNichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206
Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Metadata
- Authors
- Grof, S., Goodman, L. E., Richards, W. A., & Kurland, A. A.
- ORCID
- Richards, W.A.
- Venue
- International Pharmacopsychiatry
- Publisher
- S. Karger AG
- Published
- 2017-08-11
- Volume
- 8
- Issue
- 3
- Pages
- 129-144
- ISSN
- 0020-8272 (ISSN-L)
- 2504-2580
- OpenAlex
- W173089895
- Cited by
- 209
- References
- 0
- Citations by year
- 2026: 17 · 2025: 18 · 2024: 22 · 2023: 22 · 2022: 19 · 2021: 15 · 2020: 13 · 2019: 9 · 2018: 10 · 2017: 4
- FWCI
- 12.21
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- karger.com/pages/terms-and-conditions (vor)
- karger.com/pages/terms-and-conditions (tdm)
- Locations
- International Pharmacopsychiatry (publishedVersion)
- PubMed (publishedVersion)
- DigitalGeorgetown (Georgetown University Library) (submittedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Palliative and Oncologic Care
- Social Sciences › Health › Religion, Spirituality, and Psychology
- Keywords
- lysergic acid diethylamide, psychedelic therapy, terminal cancer, end-of-life care, depression, anxiety, psychological isolation, fear of death, pain management, emotional distress
- MeSH terms
- Adult, Aged, Anxiety, Attitude to Death, Clinical Trials as Topic, Depression, Female, Humans, Lysergic Acid Diethylamide, Male, Middle Aged, MMPI, Narcotics, Neoplasms, Palliative Care, Psychiatric Status Rating Scales, Psychotherapy, Terminal Care, Tryptamines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: LSD-Assisted Psychotherapy in Patients with Terminal Cancer. https://app.cochat.ai/papers/10.1159/000467984
- The paper
- Grof, S., Goodman, L. E., Richards, W. A., & Kurland, A. A. (2017). LSD-Assisted Psychotherapy in Patients with Terminal Cancer. International Pharmacopsychiatry. https://doi.org/10.1159/000467984
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.